New NeuroMabs (285 total in catalog):
January 27, 2012. Three new NeuroMabs have been added to the catalog (by Target and NeuroMab clone number): LRRK2/Dardarin, N-terminus (8G10); LRRK2/Dardarin-pSer910 (1D8); and THAP1 (N325B/65).
January 14, 2012. One new NeuroMab has been added to the catalog (by Target and NeuroMab clone number): Lgi1 (N283/7).
December 21, 2011. Three new NeuroMabs have been added to the catalog (by Target and NeuroMab clone number): Synaptotagmin-5 (N274/8); Synaptotagmin-9 (N276A/15) and Synaptotagmin-12 (N277/7).
November 28, 2011. Three new NeuroMabs have been added to the catalog (by Target and NeuroMab clone number): NR2A (N327A/38); Alpha-2C adrenergic receptor (N330A/80); and Dopamine D3 receptor (N331/19).
October 19, 2011. Seven new NeuroMabs have been added to the catalog (by Target and NeuroMab clone number): Notch1 (N253/32); ARHGAP4 (N290B/25); Brevican (N294A/10); SUR2A (N319A/14); SUR1 and SUR2B (N323A/31); SUR2B (N323A/51); and Alpha-2C adrenergic receptor (N330A/51).
Other news:
November 17, 2011. Thanks to all of the attendees at the recent Society for Neuroscience Annual Meeting in Washington, DC who came by the NeuroMab booth to meet and speak with Facility staff.
November 1, 2011. The new Antibodies Incorporated website catalog for NeuroMabs is now located here.
September 6, 2011. Our catalog has the most up-to-date information on new NeuroMabs, including Production and QC status and newly released catalog #'s. Because the Antibodies Incorporated website is still under construction, their NeuroMab catalog is not consistent with ours, so we will appreciate your patience until their new website goes live.
July 22, 2011. Interested users can now go here to subscribe to a mailing list and receive automatic email notifications whenever new NeuroMabs are added to our catalog.
July 14, 2011. The catalog web page has been modified for increased end user utility, by providing additional information for each NeuroMab, including the immunoglobulin isotype, and additional details on validation.
July 1, 2011. NeuroMab prices increased by $20/vial as of July 1, 2011. This reflects a requirement from NIH for partial end user support of costs associated with the generation and characterization of future NeuroMabs.
Februrary 8, 2011. We refer interested users to the Journal of Comparative Neurology Antibody Database here. This database file contains antibodies that have met the rigorous standards for publication established by JCN (see editorial here). This contains many NeuroMabs, and more will be forthcoming in later versions of the database. Thanks to JCN for providing this valuable public service.
The N52A/42 NeuroMab has been developed as a loading control for immunoblots. This anti-mortalin/GRP75 NeuroMab can be used in many tissue and cell types as a loading control as the expression of this highly conserved protein is very similar across species/tissues/cell types. See datasheet.
The NeuroMab website has been enhanced to provide summary information as to NeuroMab targets known to be mutated in human diseases (Disease Targets) and NeuroMabs tested to date for utility in non-mammalian vertebrate models (Model Organisms) (updated with new zebrafish data on 11/28/10).
Brain Maps.org and NeuroMab.org team up. Whole rat brain staining for NeuroMabs K55/7 (anti-KChIP1) and K60/73 (anti-KChIP2) is now available on the Brain Maps.org website here. NeuroMab staining in monkey brain is also presented: Macaca mulatta (here), Macaca fascicularis (here) Callecibus moloch (here).
